SCHEMBL4349366

SCHEMBL4349366

Cc1cc(O)c(N(S)C(=O)NC(C)C)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.37
CA12 O43570 3/20 0.33
CA1 P00915 3/20 0.33
CA2 P00918 3/20 0.33
CA9 Q16790 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 2/20 0.32
PTGES O14684 4/20 0.32
MAPK1 P28482 1/20 0.31
MAPK7 Q13164 1/20 0.31
CHRNA1 P02708 1/20 0.31
CHRNG P07510 1/20 0.31
CHRNB1 P11230 1/20 0.31
CHRNB2 P17787 1/20 0.31
SLC6A2 P23975 1/20 0.31
CHRNB4 P30926 1/20 0.31
SLC6A4 P31645 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4358489 0.78 SMN1; SMN2 (0.42) LMNACA1CA2SMN1; SMN2ALDH1A1
SCHEMBL4347944 0.75 ALOX5 (0.39) CA12CA1CA2CA9ALDH1A1
SCHEMBL4341634 0.72 ALDH1A1 (0.40) LMNAL3MBTL1SMN1; SMN2ALDH1A1PTGES
SCHEMBL4357469 0.72 MAPK1 (0.38) LMNACA1CA2SMN1; SMN2ALDH1A1
SCHEMBL11513064 0.72 LMNA (0.41) LMNASMN1; SMN2ALDH1A1PTGESMAPK1
SCHEMBL11512591 0.71 CA12 (0.31) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL4356000 0.69 GABRA1 (0.37) PTGES
SCHEMBL13735919 0.69 APEX1 (0.41) LMNASMN1; SMN2ALDH1A1MAPK1GAA
SCHEMBL11541475 0.68 CA12 (0.31) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL4351937 0.67 MAPK1 (0.33) ALDH1A1MAPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 LMNA 3160/4885L3MBTL1 1972/4885CA12 2054/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 LMNA 3661/4885L3MBTL1 2528/4885CA12 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.